Clinical trials: Cognition - Other
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.
- Trial name
- NCT00176423
- Testing
- galantamine
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Maryland, Baltimore
Schizoaffective Disorder, Schizophrenia
Improving Basic and Social Cognition in Veterans With Schizophrenia
Veterans with schizophrenia and schizoaffective disorder experience very high levels of disability and poor community outcome. Further improvements in community outcome for patients with these disorders will not occur simply…
- Trial name
- IBASC (NCT00470106)
- Testing
- Cognitive remediation, Social Cognitive skills training, hybrid intervention
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- VA Office of Research and Development
Psychosis, Schizophrenia
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
This clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and…
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- NCT03943537
- Testing
- Intranasal Insulin
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Schizophrenia
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
The study aims to assess the effects of single dose and repeated weekly dosing of 50mg d-cycloserine versus placebo on cognitive and memory functioning in schizophrenia patients.
- Trial name
- NCT00455702
- Testing
- d-cycloserine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone
The investigators hypothesize that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized…
- Trial name
- NCT01173874
- Testing
- Cognitive Remediation
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia
- Trial name
- NCT01009060
- Testing
- GSK239512
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Cognition
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of…
- Conditions
- Schizophrenia, Cognition, Psychosis
- Trial name
- NCT02104752
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Schizophrenia, Schizoaffective Disorder
Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.
- Trial name
- NCT01658150
- Testing
- isradipine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia, Schizoaffective Disorder
Salsalate as an Adjunctive Treatment for Patients With Schizophrenia
This is a 12-week, open-label trial of salsalate 3 g/day as an adjunctive treatment in 15 schizophrenia subjects to examine salsalate's effect on psychopathology, cognitive functioning, and metabolic parameters.
- Trial name
- NCT01578486
- Testing
- salsalate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic…
- Trial name
- NCT02832037
- Testing
- BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3
- Where
- 81 sites in United States, Austria and 9 more
- Volunteers
- 509 people
- Sponsor
- Boehringer Ingelheim
Cognition in Schizophrenia
Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving.
- Trial name
- NCT00628394
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia
The Effects of Nicotine on Cognition in Schizophrenia
Patients with schizophrenia have a variety cognitive deficits and nicotine has been shown to normalize some of these deficits. The purpose of this study is to investigate the effects of nicotine on cognition in schizophrenia.We…
- Trial name
- NCT00383747
- Testing
- transdermal nicotine patch
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorders
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
- Trial name
- NCT01082588
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizophreniform Disorder
rTMS in First Episode Psychosis
This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- EmeraldThunder (NCT02131129)
- Testing
- rTMS
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Psychoses, Substance-Induced
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal respiratory depression in comparison to other available…
- Trial name
- NCT00205712
- Testing
- Ketamine, Dexmedetomidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Schizophrenia
Intranasal Insulin Treatment in Patients With Schizophrenia
This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia subjects to examine insulin's effect on…
- Trial name
- NCT00575666
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia, Cigarette Smoking
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with…
- Trial name
- NCT00802919
- Testing
- Varenicline
- Where
- 4 sites in United States, China and 1 more
- Volunteers
- 93 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions.
- Trial name
- NCT01312272
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Schizophrenia, Schizoaffective Disorder
Nicotinic Receptors and Schizophrenia
The investigators hypothesize that sustained-release DMXB-A-SR (3-2,4 dimethoxybenzylidene anabaseine sustained release) will provide clinical improvement in cognition in patients with schizophrenia who are smokers and who are…
- Trial name
- NCT01400477
- Testing
- DMXB-A-SR
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- University of Colorado, Denver
Schizophrenia, Schizoaffective Disorder
Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
The goals of this study are to study MMFS-202-302 in a double blind, randomized, placebo-controlled 9-week study of its effect on ameliorating cognitive deficits in 60 patients with schizophrenia or schizoaffective disorder with…
- Trial name
- NCT02237235
- Testing
- MMFS-202-302
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University